107 related articles for article (PubMed ID: 11324348)
21. Lepirudin in heparin-induced thrombocytopenia and extracorporeal membranous oxygenation.
Dager WE; Gosselin RC; Yoshikawa R; Owings JT
Ann Pharmacother; 2004 Apr; 38(4):598-601. PubMed ID: 14982973
[TBL] [Abstract][Full Text] [Related]
22. [Heparin elimination and free hemoglobin following cell separation and washing of autologous blood with Cell Saver 4].
Kling D; Börner U; von Bormann B; Hempelmann G
Anasth Intensivther Notfallmed; 1988 Apr; 23(2):88-90. PubMed ID: 3394905
[TBL] [Abstract][Full Text] [Related]
23. [Heparin-induced thrombocytopenia type II. Intra- and postoperative lepirudin treatment in acute ischemia of the extremities].
Schmidt O; Lang W
Dtsch Med Wochenschr; 1998 Oct; 123(41):1207-10. PubMed ID: 9810286
[TBL] [Abstract][Full Text] [Related]
24. Lepirudin: a bivalent direct thrombin inhibitor for anticoagulation therapy.
Greinacher A
Expert Rev Cardiovasc Ther; 2004 May; 2(3):339-57. PubMed ID: 15151481
[TBL] [Abstract][Full Text] [Related]
25. Point of care measurement of lepirudin and heparin anticoagulation during systemic inflammation.
Homoncik M; Pernerstorfer T; Reiter R; Knechtelsdorfer M; Quehenberger P; Jilma B
Thromb Res; 2002 Oct; 108(1):91-5. PubMed ID: 12586138
[TBL] [Abstract][Full Text] [Related]
26. Use of lepirudin during percutaneous vascular interventions in patients with heparin-induced thrombocytopenia.
Cochran K; DeMartini TJ; Lewis BE; O Brien J; Steen LH; Grassman ED; Leya F
J Invasive Cardiol; 2003 Nov; 15(11):617-21. PubMed ID: 14608129
[TBL] [Abstract][Full Text] [Related]
27. Alteration of pharmacokinetics of lepirudin caused by anti-lepirudin antibodies occurring after long-term subcutaneous treatment in a patient with recurrent VTE due to Behcets disease.
Linnemann B; Greinacher A; Lindhoff-Last E
Vasa; 2010 Feb; 39(1):103-7. PubMed ID: 20186683
[TBL] [Abstract][Full Text] [Related]
28. Monitoring of anticoagulant effects of direct thrombin inhibitors.
Fenyvesi T; Jörg I; Harenberg J
Semin Thromb Hemost; 2002 Aug; 28(4):361-8. PubMed ID: 12244483
[TBL] [Abstract][Full Text] [Related]
29. Risk of anaphylaxis after reexposure to intravenous lepirudin in patients with current or past heparin-induced thrombocytopenia.
Cardenas GA; Deitcher SR
Mayo Clin Proc; 2005 Apr; 80(4):491-3. PubMed ID: 15819285
[TBL] [Abstract][Full Text] [Related]
30. Bidirectional glenn shunt surgery using lepirudin anticoagulation in an infant with heparin-induced thrombocytopenia with thrombosis.
Iannoli ED; Eaton MP; Shapiro JR
Anesth Analg; 2005 Jul; 101(1):74-6, table of contents. PubMed ID: 15976209
[TBL] [Abstract][Full Text] [Related]
31. Characterization of the postglomerular renal metabolism of lepirudin in healthy volunteers.
Kautzleben M; Stein G; Sperschneider H; Nowak G
Thromb Res; 2004; 113(3-4):187-95. PubMed ID: 15140582
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of treatment with direct thrombin inhibitors in patients with heparin-induced thrombocytopenia.
Dang CH; Durkalski VL; Nappi JM
Pharmacotherapy; 2006 Apr; 26(4):461-8. PubMed ID: 16553503
[TBL] [Abstract][Full Text] [Related]
33. Blood conservation for myocardial revascularization. Is it cost effective?
Breyer RH; Engelman RM; Rousou JA; Lemeshow S
J Thorac Cardiovasc Surg; 1987 Apr; 93(4):512-22. PubMed ID: 3104693
[TBL] [Abstract][Full Text] [Related]
34. Lepirudin dose-dependently increases thrombelastography parameters at therapeutic plasma concentrations as measured with ROTEM® - a pilot study.
Feuring M; Wehling M; Schultz A
Int J Clin Pharmacol Ther; 2011 Oct; 49(10):626-8. PubMed ID: 21961488
[TBL] [Abstract][Full Text] [Related]
35. Severe anaphylactic reaction after repeated intermittent exposure to lepirudin.
Veach SA; Franks AM; Allan MC
Pharmacotherapy; 2007 May; 27(5):760-5. PubMed ID: 17461712
[TBL] [Abstract][Full Text] [Related]
36. [Biventricular thrombus resolution and antibody formation during lepirudin therapy. Comment on the article from DMW 28-29/2003].
Nowak G
Dtsch Med Wochenschr; 2003 Nov; 128(45):2389-90; author reply 2390. PubMed ID: 14606040
[No Abstract] [Full Text] [Related]
37. [Use of ecarin clotting time in whole blood for monitoring recombinant hirudine treatment during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia].
Devignes J; de Maistre E; Grosjean S; Walter AF; Hacquard M; Mulot A; Longrois D; Carteaux JP; Lecompte T
Ann Biol Clin (Paris); 2005; 63(2):201-8. PubMed ID: 15771978
[TBL] [Abstract][Full Text] [Related]
38. Use of heparin versus lepirudin flushes to prevent withdrawal occlusion of central venous access devices.
Horne MK; McCloskey DJ; Calis K; Wesley R; Childs R; Kasten-Sportes C
Pharmacotherapy; 2006 Sep; 26(9):1262-7. PubMed ID: 16945048
[TBL] [Abstract][Full Text] [Related]
39. [Treatment by lepirudin and acenocoumarol of heparin induced thrombocytopenia after valvular surgery: a word of caution].
Lehot JJ; Gostoli B; Ffrench P; Berruyer M; Hanss M
Ann Fr Anesth Reanim; 2006; 25(11-12):1140-3. PubMed ID: 17174212
[TBL] [Abstract][Full Text] [Related]
40. [Hirudins in the treatment of heparin-induced thrombocytopenia and in thrombosis prophylaxis].
Lubenow N; Greinacher A
Hamostaseologie; 2002 Aug; 22(3):44-54. PubMed ID: 12215761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
